Hemophilia A Treatment Market analysis from 2019 to 2026 explored in latest research

Posted November 20, 2019 by KrystleLora

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics.

New York, NY 20 Nov 2019 :Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.

Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.

Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-sample

RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.

Polaris Market Research has provided the forecasts of the Global Hemophilia A Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

Market Analysis by Hemophilia A treatment
Market Analysis by Treatments/Marketed Drugs
Market Analysis by G7 countries
The Marketed Therapies undertaken in forecast from 2016-2022 are:

Afstyla Sales Forecast-2016-2022
Eloctate Sales Forecast-2016-2022
Hemlibra Sales Forecast-2016-2022
Kogenate FS Sales Forecast-2016-2022
Kovaltry Sales Forecast-2016-2022
Nuwiq Sales Forecast-2016-2022
Obizur Sales Forecast-2016-2022
The Major Indications in Hemophilia A Therapy area:

Prophylaxis-Market Forecast 2016-2022
On-demand therapy-Market Forecast 2016-2022
Inhibitor therapy- Market Forecast 2016-2022
The Market Forecast of Hemophilia A Treatment by G7 Countries (2016-2022)

United States- Market Forecast (2016-2022)
Germany- Market Forecast (2016-2022)
France-Market Forecast (2016-2022)
Italy- Market Forecast (2016-2022)
Spain- Market Forecast (2016-2022)
United Kingdom- Market Forecast (2016-2022)
Japan- Market Forecast (2016-2022)
Leading Companies investigated in the Report are

CSL Behring
Alnylam Pharmaceuticals
Sanofi (Genzyme)
BioMarin Pharmaceutical
Hoffmann-La Roche
Sinocelltech Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Novo Nordisk A/S
Get Exclusive Discount on This Report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavour to deliver value-added business solutions to our customers.

Contact Us:

Mr. Likhil

Corporate Sales, USA

Polaris Market Research

Phone: 1-646-568-9980

Email: [email protected]

Web: www.polarismarketresearch.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By yamini
Phone 6467362939
Business Address 30 Wall Street 8th Floor, New York City, NY 10005, United States
Country United States
Categories Blogging , Marketing , Technology
Last Updated November 20, 2019